BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu Y, Zhu Y, Lu NH. Recent progress in Helicobacter pylori treatment. Chin Med J (Engl). 2020;133:335-343. [PMID: 31929363 DOI: 10.1097/cm9.0000000000000618] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Abdulfattah AA, Jawkhab HA, Alhazmi AA, Alfaifi NA, Sultan MA, Alnami RA, Kenani NY, Hamzi SA, Abu Sharha SM, Dighriri IM. The Association of Smoking and Coffee Consumption With Occurrence of Upper Gastrointestinal Symptoms in Patients With Active Helicobacter pylori Infection in Jazan City: A Cross-Sectional Study. Cureus 2023. [DOI: 10.7759/cureus.33574] [Reference Citation Analysis]
2 Wang YZ, Chen J, Pei SQ, Wang C, Han G, Kan LD, Li LC. Treatment strategies and pharmacist-led medication management for Helicobacter pylori infection. Drug Dev Res 2022. [PMID: 36567647 DOI: 10.1002/ddr.22025] [Reference Citation Analysis]
3 Yang H, Guan L, Hu B, Moreira L. Detection and Treatment of Helicobacter pylori: Problems and Advances. Gastroenterology Research and Practice 2022;2022:1-10. [DOI: 10.1155/2022/4710964] [Reference Citation Analysis]
4 Shchelochenkov SV, Guskova ON, Bordin DS. Clinical-endoscopic and morphological aspects of autoimmune gastritis. jour 2022. [DOI: 10.31146/1682-8658-ecg-200-4-14-19] [Reference Citation Analysis]
5 Ouyang Y, Wang M, Xu YL, Zhu Y, Lu NH, Hu Y. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. J Gastroenterol Hepatol 2022;37:1666-72. [PMID: 35716370 DOI: 10.1111/jgh.15917] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
6 Prada CF, Casadiego MA, Freire CC. Evolution of Helicobacter spp: variability of virulence factors and their relationship to pathogenicity. PeerJ 2022;10:e13120. [PMID: 36061745 DOI: 10.7717/peerj.13120] [Reference Citation Analysis]
7 Sukati S, Sama-ae I, Katzenmeier G, Wisessombat S. Evaluation of Susceptibility of the Human Pathogen Helicobacter pylori to the Antibiotic Capreomycin. The Scientific World Journal 2022;2022:1-12. [DOI: 10.1155/2022/8924023] [Reference Citation Analysis]
8 Cho JH, Jin SY. Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea. World J Clin Cases 2022; 10(19): 6349-6359 [DOI: 10.12998/wjcc.v10.i19.6349] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Garrido-treviño L, López-martínez M, Flores-hinojosa J, Tijerina-rodríguez L, Bosques-padilla F. Tratamiento empírico vs tratamiento basado en susceptibilidad para erradicar H.pylori: ¿es posible cambiar este paradigma usando métodos moleculares modernos? Revista de Gastroenterología de México 2022;87:330-341. [DOI: 10.1016/j.rgmx.2022.01.007] [Reference Citation Analysis]
10 Garrido-treviño L, López-martínez M, Flores-hinojosa J, Tijerina-rodríguez L, Bosques-padilla F. Empiric treatment vs susceptibility-guided treatment for eradicating H. pylori: Is it possible to change that paradigm using modern molecular methods? Revista de Gastroenterología de México (English Edition) 2022;87:330-341. [DOI: 10.1016/j.rgmxen.2022.06.003] [Reference Citation Analysis]
11 Jin F, Yang H. Transcriptome Analysis of the Response of Mature Helicobacter pylori Biofilm to Different Doses of Lactobacillus salivarius LN12 with Amoxicillin and Clarithromycin. Antibiotics 2022;11:262. [DOI: 10.3390/antibiotics11020262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Ding SZ, Du YQ, Lu H, Wang WH, Cheng H, Chen SY, Chen MH, Chen WC, Chen Y, Fang JY, Gao HJ, Guo MZ, Han Y, Hou XH, Hu FL, Jiang B, Jiang HX, Lan CH, Li JN, Li Y, Li YQ, Liu J, Li YM, Lyu B, Lu YY, Miao YL, Nie YZ, Qian JM, Sheng JQ, Tang CW, Wang F, Wang HH, Wang JB, Wang JT, Wang JP, Wang XH, Wu KC, Xia XZ, Xie WF, Xie Y, Xu JM, Yang CQ, Yang GB, Yuan Y, Zeng ZR, Zhang BY, Zhang GY, Zhang GX, Zhang JZ, Zhang ZY, Zheng PY, Zhu Y, Zuo XL, Zhou LY, Lyu NH, Yang YS, Li ZS; National Clinical Research Center for Digestive Diseases (Shanghai), Gastrointestinal Early Cancer Prevention & Treatment Alliance of China (GECA), Helicobacter pylori Study Group of Chinese Society of Gastroenterology, and Chinese Alliance for Helicobacter pylori Study. Chinese Consensus Report on Family-Based Helicobacter pylori Infection Control and Management (2021 Edition). Gut 2022;71:238-53. [PMID: 34836916 DOI: 10.1136/gutjnl-2021-325630] [Cited by in Crossref: 12] [Cited by in F6Publishing: 27] [Article Influence: 12.0] [Reference Citation Analysis]
13 Cai X, Li X, Jin Y, Zhang M, Xu Y, Liang C, Weng Y, Yu W, Li X. Vitamins and Helicobacter pylori: An Updated Comprehensive Meta-Analysis and Systematic Review. Front Nutr 2022;8:781333. [DOI: 10.3389/fnut.2021.781333] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lai Y, Wei W, Du Y, Gao J, Li Z. Biomaterials for Helicobacter pylori therapy: therapeutic potential and future perspectives. Gut Microbes 2022;14:2120747. [PMID: 36070564 DOI: 10.1080/19490976.2022.2120747] [Reference Citation Analysis]
15 Tshimpi A, Ngoma-kisoko PDJ, Beia A, Kalenga-ngomba T, Nkondi J, Bokabanja F, Mawalala H, Monsere T, Kengibe P, Nkanga MN, Longo-mbenza B. Assessing of the Therapeutic Efficacy of These 2 Treatment Regimens in the Management of <i>Helicobacter pylori</i> Infection at Kinshasa. OJGas 2022;12:71-87. [DOI: 10.4236/ojgas.2022.123008] [Reference Citation Analysis]
16 Zhang X, Sang S, Guan Q, Tao H, Wang Y, Liu C. Identification of B-Cell Epitopes of HspA from Helicobacter pylori and Detection of Epitope Antibody Profiles in Naturally Infected Persons. Vaccines (Basel) 2021;10:65. [PMID: 35062726 DOI: 10.3390/vaccines10010065] [Reference Citation Analysis]
17 Penumetcha SS, Ahluwalia S, Irfan R, Khan SA, Rohit Reddy S, Vasquez Lopez ME, Zahid M, Busmail A, Mohammed L. The Efficacy of Probiotics in the Management of Helicobacter Pylori: A Systematic Review. Cureus 2021;13:e20483. [PMID: 35047301 DOI: 10.7759/cureus.20483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Teresa Mascellino M, De Angelis M, Al Ismail D, Oliva A. Virulence Markers, Genotypic versus Phenotypic Resistance and New Treatment Strategies in Helicobacter pylori Infection. Helicobacter pylori - From First Isolation to 2021 2021. [DOI: 10.5772/intechopen.97026] [Reference Citation Analysis]
19 Bakhshipour A, Rafaiee R. Prevalence of Idiopathic Peptic Ulcer in Southeastern Iran. Zahedan J Res Med Sci 2021;In Press. [DOI: 10.5812/zjrms.119598] [Reference Citation Analysis]
20 Krzyżek P, Junka A, Słupski W, Dołowacka-Jóźwiak A, Płachno BJ, Sobiecka A, Matkowski A, Chodaczek G, Płusa T, Gościniak G, Zielińska S. Antibiofilm and Antimicrobial-Enhancing Activity of Chelidonium majus and Corydalis cheilanthifolia Extracts against Multidrug-Resistant Helicobacter pylori. Pathogens 2021;10:1033. [PMID: 34451497 DOI: 10.3390/pathogens10081033] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
21 Mladenova I. Clinical Relevance of Helicobacter pylori Infection. J Clin Med 2021;10:3473. [PMID: 34441769 DOI: 10.3390/jcm10163473] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 7.5] [Reference Citation Analysis]
22 Jin F, Yang H. Effects of Lactobacillus salivarius LN12 in Combination with Amoxicillin and Clarithromycin on Helicobacter pylori Biofilm In Vitro. Microorganisms 2021;9:1611. [PMID: 34442690 DOI: 10.3390/microorganisms9081611] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Yang H, Hu B. Diagnosis of Helicobacter pylori Infection and Recent Advances. Diagnostics (Basel) 2021;11:1305. [PMID: 34441240 DOI: 10.3390/diagnostics11081305] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
24 Gao W, Zhang X, Yin Y, Yu S, Wang L. Different dose of new generation proton pump inhibitors for the treatment of Helicobacter pylori infection: A meta-analysis. Int J Immunopathol Pharmacol 2021;35:20587384211030397. [PMID: 34250840 DOI: 10.1177/20587384211030397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Kuo CF, Shi L, Lin CL, Yao WC, Chen HT, Lio CF, Wang YT, Su CH, Hsu NW, Tsai SY. How peptic ulcer disease could potentially lead to the lifelong, debilitating effects of chronic fatigue syndrome: an insight. Sci Rep 2021;11:7520. [PMID: 33824394 DOI: 10.1038/s41598-021-87018-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
26 Hu Y, Ouyang Y, Zhu Y, Lu NH. Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Helicobacter 2021;26:e12784. [PMID: 33534148 DOI: 10.1111/hel.12784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Sánchez-Alonzo K, Belmar L, Parra-Sepúlveda C, Bernasconi H, Campos VL, Smith CT, Sáez K, García-Cancino A. Antibiotics as a Stressing Factor Triggering the Harboring of Helicobacter pylori J99 within Candida albicans ATCC10231. Pathogens 2021;10:382. [PMID: 33806815 DOI: 10.3390/pathogens10030382] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
28 Palencia M, Lerma TA, Garcés V, Mora MA, Martínez JM, Palencia SL. Polymeric drug carriers against Helicobacter pylori. Eco-friendly Functional Polymers 2021. [DOI: 10.1016/b978-0-12-821842-6.00006-3] [Reference Citation Analysis]
29 Raina H, Sainani R, Parray A, Wani AH, Asharaf U, Raina MA. Efficacy of levofloxacin, omeprazole, nitazoxanide, and doxycycline (LOAD) regimen compared with standard triple therapy to eradicate Helicobacter pylori infection: a prospective randomized study from a tertiary hospital in India. Gastroenterol Hepatol Bed Bench 2021;14:342-8. [PMID: 34659662] [Reference Citation Analysis]
30 Ye ZN, Xia HH, Zhang R, Li L, Wu LH, Liu XJ, Xie WR, He XX. The Efficacy of Washed Microbiota Transplantation on Helicobacter pylori Eradication: A Pilot Study. Gastroenterol Res Pract 2020;2020:8825189. [PMID: 33133183 DOI: 10.1155/2020/8825189] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
31 Krzyżek P, Paluch E, Gościniak G. Synergistic Therapies as a Promising Option for the Treatment of Antibiotic-Resistant Helicobacter pylori. Antibiotics (Basel) 2020;9:E658. [PMID: 33007899 DOI: 10.3390/antibiotics9100658] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
32 Yan TL, Gao JG, Wang JH, Chen D, Lu C, Xu CF. Current status of Helicobacter pylori eradication and risk factors for eradication failure. World J Gastroenterol 2020; 26(32): 4846-4856 [PMID: 32921961 DOI: 10.3748/wjg.v26.i32.4846] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
33 Mascellino MT, Oliva A, Miele MC, De Angelis M, Bruno G, Severi C. Secondary Antibiotic Resistance, Correlation between Genotypic and Phenotypic Methods and Treatment in Helicobacter pylori Infected Patients: A Retrospective Study. Antibiotics (Basel) 2020;9:E549. [PMID: 32872117 DOI: 10.3390/antibiotics9090549] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
34 Duda-Madej A, Kozłowska J, Krzyżek P, Anioł M, Seniuk A, Jermakow K, Dworniczek E. Antimicrobial O-Alkyl Derivatives of Naringenin and Their Oximes Against Multidrug-Resistant Bacteria. Molecules 2020;25:E3642. [PMID: 32785151 DOI: 10.3390/molecules25163642] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
35 Song Z, Li B, Zhang Y, Li R, Ruan H, Wu J, Liu Q. Outer Membrane Vesicles of Helicobacter pylori 7.13 as Adjuvants Promote Protective Efficacy Against Helicobacter pylori Infection. Front Microbiol 2020;11:1340. [PMID: 32733396 DOI: 10.3389/fmicb.2020.01340] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]